- Home
- IBG vs OGEN Comparison
IBG vs OGEN Comparison
Compare IBG & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- OGEN
- Stock Information
- Founded
- IBG 2018
- OGEN 1996
- Country
- IBG Australia
- OGEN United States
- Employees
- IBG N/A
- OGEN N/A
- Industry
- IBG Beverages (Production/Distribution)
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- IBG Consumer Staples
- OGEN Health Care
- Exchange
- IBG Nasdaq
- OGEN Nasdaq
- Market Cap
- IBG 4.1M
- OGEN 4.6M
- IPO Year
- IBG 2024
- OGEN N/A
- Fundamental
- Price
- IBG $0.72
- OGEN $0.20
- Analyst Decision
- IBG Strong Buy
- OGEN
- Analyst Count
- IBG 1
- OGEN 0
- Target Price
- IBG N/A
- OGEN N/A
- AVG Volume (30 Days)
- IBG 12.0M
- OGEN 376.3K
- Earning Date
- IBG 05-15-2025
- OGEN 05-14-2025
- Dividend Yield
- IBG N/A
- OGEN N/A
- EPS Growth
- IBG N/A
- OGEN N/A
- EPS
- IBG N/A
- OGEN N/A
- Revenue
- IBG $3,147,763.00
- OGEN N/A
- Revenue This Year
- IBG N/A
- OGEN N/A
- Revenue Next Year
- IBG N/A
- OGEN N/A
- P/E Ratio
- IBG N/A
- OGEN N/A
- Revenue Growth
- IBG N/A
- OGEN N/A
- 52 Week Low
- IBG $0.44
- OGEN $0.16
- 52 Week High
- IBG $3.35
- OGEN $3.43
- Technical
- Relative Strength Index (RSI)
- IBG N/A
- OGEN 43.74
- Support Level
- IBG N/A
- OGEN $0.16
- Resistance Level
- IBG N/A
- OGEN $0.21
- Average True Range (ATR)
- IBG 0.00
- OGEN 0.01
- MACD
- IBG 0.00
- OGEN 0.00
- Stochastic Oscillator
- IBG 0.00
- OGEN 74.00
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter and retailer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.